The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B

2020 ◽  
Author(s):  
Chien‐Wei Peng ◽  
Wen‐Juei Jeng ◽  
Rong‐Nan Chien ◽  
Yun‐Fan Liaw
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
First Year ◽  
Hbeag Loss ◽  
Hepatitis Flare ◽  
The Impact

scholarly journals Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Xiao-Jun Zhu ◽  
Xue-Hua Sun ◽  
Zheng-Hua Zhou ◽  
Shun-Qing Liu ◽  
Hua Lv ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Treatment Group ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Alanine Aminotransferase ◽  
Hbv Dna ◽  
Control Group ◽  
Hbeag Loss ◽  
Histological Improvement ◽  
Positive Chronic Hepatitis

Objective. To determine the efficacy and safety of Lingmao Formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase (ALT).Methods. 301 patients were randomly assigned to receive Lingmao Formula combined with entecavir (treatment group) or placebo combined with entecavir (control group) for 52 weeks. The outcomes of interest included the reduction of serum HBV DNA level, HBeAg loss, HBeAg seroconversion, ALT normalization, and histological improvement.Results. The mean decrease of serum HBV DNA level from baseline and the percentage of patients who had reduction in serum HBV DNA level ≥2 lg copies/mL in treatment group were significantly greater than that in control group (5.5 versus 5.4 lg copies/mL,P=0.010; 98.5% versus 92.6%,P=0.019). The percentage of HBeAg loss in treatment group was 22.8%, which was much higher than a percentage of 12.6% in control group (P=0.038). There was no significant difference between the two groups in histological improvement. Safety was similar in the two groups.Conclusions. The combination of Lingmao Formula with entecavir could result in significant decrease of serum HBV DNA and increase of HBeAg loss for HBeAg-positive chronic hepatitis B patients with mildly elevated ALT without any serious adverse events. Clinical trial registration number isChiCTR-TRC-09000594.

scholarly journals Study of the Impact of Hepatitis D Virus Infection on Chronic Hepatitis B Virus Patients in Egypt

2016 ◽  
Vol 5 (2) ◽  
pp. 449-458 ◽  
Author(s):  
Mohamed Abdel-Hamid Ahmed ◽  
MostafaSaleh Abdel-Motaleb Sheemy ◽  
Nagwa Sedky ◽  
Gamal Esmat ◽  
Azza Abdul-Azim Gomaa
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
The Impact

scholarly journals Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: A preliminary finding

2020 ◽  
Author(s):  
Shi‐Chi Wen ◽  
Chi‐Chang Tsai ◽  
Lung‐Chih Cheng ◽  
Chien‐Wei Huang ◽  
Wu‐Hsien Kuo
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Preliminary Finding ◽  
Hbeag Loss

scholarly journals Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation

2010 ◽  
Vol 5 (1) ◽  
pp. 586-596 ◽  
Author(s):  
Cheng-Yuan Peng ◽  
Chih-Bin Chen ◽  
Hsueh-Chou Lai ◽  
Wen-Pang Su ◽  
Po-Heng Chuang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Acute Exacerbation ◽  
Chronic Hepatitis B ◽  
Lamivudine Therapy ◽  
Hbeag Loss ◽  
Positive Chronic Hepatitis

1153 The impact of interferon-alfa (IFNA) therapy on liver histology in patients with HBEAG-negative chronic hepatitis B [HBEAG(-)CHB]

Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 712-712
Author(s):  
G PAPATHEODORIDIS ◽  
E CHOLONGITAS ◽  
E KANTA ◽  
K PETRAKI ◽  
I KETIKOGLOU ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interferon Alfa ◽  
Liver Histology ◽  
Ifna Therapy ◽  
The Impact ◽  
Negative Chronic Hepatitis

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C

2003 ◽  
Vol 39 (6) ◽  
pp. 1063-1069 ◽  
Author(s):  
Yasuhiro Asahina ◽  
Namiki Izumi ◽  
Masakatsu Uchihara ◽  
Osamu Noguchi ◽  
Yuki Nishimura ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Core Promoter ◽  
Hbeag Loss ◽  
Genotype C
Sign in / Sign up

Export Citation Format

Share Document